Case Number 3517
Request Date 04/03/2014
Completion Date 01/04/2014

 

Details of the Request

We are conducting a piece of research into the use of biologics in the treatment of psoriasis and psoriatic arthropathies and rheumatoid arthritis. Under the Freedom of Information Act 2000 we would like to request the following information for patients under your care between 1st April 2013 and 31st August 2013

  1. Number of patients with psoriasis and psoriatic arthropathies being treated with any of the following drugs
     
  2. Number of patients with psoriasis and psoriatic arthropathies being treated with any of the following drugs receiving their medication from the Hospital Pharmacy via a Hospital Outpatient prescription form
     
  3. Number of patients with psoriasis and psoriatic arthropathies being treated with any of the following drugs receiving their medication via a FP10 (Hospital) for presentation at a Community Pharmacy
     
  4. Number of patients with psoriasis and psoriatic arthropathies being treated with any of the following drugs receiving their medication through a Home Healthcare Delivery Service

Drug:

  • Adalimimab
  • Golimumab
  • Etanercept
  • Infliximab
  • Ustekinumab

 

  1. Number of patients with rheumatoid arthritis being treated with any of the following drugs
     
  2. Number of patients with rheumatoid arthritis being treated with any of the following drugs receiving their medication from the Hospital Pharmacy via a Hospital Outpatient prescription form
     
  3. Number of patients with rheumatoid arthritis being treated with any of the following drugs receiving their medication via a FP10 (Hospital) for presentation at a Community Pharmacy
     
  4. Number of patients with rheumatoid arthritis being treated with any of the following drugs receiving their medication through a Home Healthcare Delivery Service
  • Adalimimab
  • Abatacept
  • Belimumab
  • Etanercept
  • Infliximab
  • Rituximab
  • Tocilizumab
  • Certolizumab

 

Details of the Response

 See attached.